根據 4 位華爾街分析師的預測,AddLife AB 的收入預期範圍從 $2.98B 到 $2.67B
AddLife AB 的盈利品質評分是多少?
AddLife AB 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
AddLife AB 何時發布財報?
AddLife AB 的下一份財報預計在 2026-05-05 發布
AddLife AB 的預期收益是多少?
根據華爾街分析師的預測,AddLife AB 的預期收益為 $2.82B
AddLife AB 是否超出收益預期?
AddLife AB 最近的收益為 $2.73B,未達預期 預期。
關鍵數據
前收市價
--
開盤價
--
當日範圍
-
52週區間
-
交易量
--
平均成交量
--
股息收益率
--
每股盈餘 (TTM)
--
市值
--
什麼是 ADDLY?
AddLife AB engages in the ownership and acquisition of firms in niche segments under the healthcare sector. The company is headquartered in Stockholm, Stockholm and currently employs 2,295 full-time employees. The company went IPO on 2015-03-16. The firm markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The firm operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The firm operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.